Komori
Susmed (4263) · FactDropped

No product has yet reached the approval or commercialization stage

First written in FY2022-Q2. 12 of 22 entries say "Restated". Latest entry: FY2026.

22entries
5years
9from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q2 – 2026-05-082022: 420222023: 420232024: 220242025: 120252026: 112026
Same theme, other companies
Risk of business losses due to the absence of marketing-authorized products and failure to obtain approvalA theme 2 companies write about · 2 as a headwind · 0 as a tailwind

0 other companies' latest entry also says "Dropped".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026DroppedAnnual report

    「Sales of the “サスメド insomnia disorder app Medcle®” began in June 2026.」

    The situation changed from having no product at the approval and sales stage to the launch of sales of the insomnia disorder app.
  3. FY2026-H1RestatedAnnual report

    「There are still no products at the sales stage.」

    Although preparations are underway for insurance coverage and the launch of the insomnia treatment app, and various clinical research projects have progressed, the company continues to have no product at the sales stage.
  4. FY2025-H1RestatedAnnual report

    「There are still no products at the sales stage.」

    Although the insomnia treatment app has obtained approval and various clinical research projects have progressed, the company continues to have no product at the sales stage.
  5. FY2024-Q3RestatedAnnual report

    「There are still no products at the sales stage.」

    Although the company has begun clinical research on a tinnitus treatment app and has progressed with the recognition of contract revenue, it explains that no product has yet reached the sales stage.
  6. FY2024-Q2RestatedAnnual report

    「There are still no products at the sales stage.」

    Even after obtaining approval for the insomnia treatment app, the company states that no product has yet reached the sales stage.
  7. FY2024-Q1RestatedAnnual report

    「There are still no products at the sales stage.」

    Even after obtaining approval for the insomnia treatment app, the company states that no product has yet reached the sales stage.
  8. FY2023RestatedAnnual report

    「There are still no products at the sales stage.」

    Even after obtaining approval for the insomnia treatment app, the company states that no product has yet reached the sales stage.
  9. FY2023-Q3RestatedAnnual report

    「There are still no products at the sales stage.」

    Even after obtaining approval for the insomnia treatment app, the company states that no product has yet reached the sales stage.
  10. FY2023-Q2RestatedAnnual report

    「There are still no products at the sales stage.」

    Even after approval of the insomnia treatment app, the company states that no product has yet reached the sales stage.
  11. FY2023-Q1RestatedAnnual report

    「No product that has obtained medical device approval has yet reached the sales stage.」

    The company reiterates that no product has obtained regulatory approval and reached the sales stage.
  12. FY2022RestatedAnnual report

    「Although we have obtained medical device approval, no product has yet reached the sales stage,」

    The company reiterates that no product has yet obtained approval and reached the sales stage.
  13. FY2022-Q3RestatedAnnual report

    「Although we have obtained medical device approval, no product has yet reached the sales stage,」

    Although the application for regulatory approval and the sales partnership agreement are progressing, the company reiterates that no product has obtained approval and reached the sales stage.
  14. FY2022-Q2First statedAnnual report

    「Although we have obtained medical device approval, no product has yet reached the sales stage,」

    Although the approval application and sales partnership agreement for the insomnia treatment app are progressing, the company states that as of the filing date it had no product that had obtained approval and reached the sales stage.
Moved together

"Regulatory approval for a digital therapeutic app for insomnia and preparations for insurance reimbursement" moved the same way as this thread, in the same document, in 4 of its 22 moves.

433222★123456
  1. ★This thread
  2. 1Regulatory approval for a digital therapeutic app for insomnia and preparations for insurance reimbursement4×
  3. 2Use of a clinical trial system implementing blockchain technology3×
  4. 3Provision of a General-Purpose Clinical Trial System and a Machine-Learning-Based Automated Analysis System3×
  5. 4Stabilizing Platform Revenue by Increasing the Number of Companies That Continue to Use the Platform2×
  6. 5Research and development, regulatory approval and insurance reimbursement for a therapeutic app in otolaryngology2×
  7. 6Joint Development and Exclusive Sales Partnership with Kyorin Pharmaceutical for an Otolaryngology Therapeutic App2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Susmed yet. It last moved in the Management plan of 2026-09-17: "Achieved".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
No product has yet reached the approval or commercialization stage | SUSMED,Inc. (4263) | Komori